Revvity, Inc. (RVTY) is a publicly traded Healthcare sector company. As of May 20, 2026, RVTY trades at $94.89 with a market cap of $10.65B and a P/E ratio of 46.01. RVTY moved -0.97% today. Year to date, RVTY is -7.11%; over the trailing twelve months it is +1.30%. Its 52-week range spans $81.22 to $129.50. Analyst consensus is buy with an average price target of $104.75. Rallies surfaces RVTY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Revvity jumps after Q1 EPS beat as investors look past lowered 2026 outlook: Revvity shares are higher after its Q1 2026 results beat expectations on adjusted EPS, helping offset mixed reactions to a lower full-year profit outlook. The company also highlighted portfolio actions, including plans to divest its China Immunodiagnostics business.
| Metric | Value |
|---|---|
| Price | $94.89 |
| Market Cap | $10.65B |
| P/E Ratio | 46.01 |
| EPS | $2.07 |
| Dividend Yield | 0.07% |
| 52-Week High | $129.50 |
| 52-Week Low | $81.22 |
| Volume | 1.05M |
| Avg Volume | 0 |
| Revenue (TTM) | $2.86B |
| Net Income | $241.20M |
| Gross Margin | 0.00% |
10 analysts cover RVTY: 0 strong buy, 3 buy, 7 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $104.75.